Tag: Alexion

FDA, Regulations

AstraZeneca gets FDA OK for rare disease drug acquired in Alexion buyout

April 1, 2024

Via: Biopharma Dive

The Food and Drug Administration has approved a first-of-its-kind drug for people with the rare and serious blood disease paroxysmal nocturnal hemoglobinuria, or PNH. Called Voydeya and owned by AstraZeneca, the drug is cleared for use as an add-on therapy […]

Cell and Gene Therapy, Industry

Alexion Completes Purchase and License Agreement of Rare Disease Gene Therapy Portfolio from Pfizer

September 21, 2023

Via: Biopharm International

On Sept. 20, 2023, Alexion, AstraZeneca’s rare disease group, completed the purchase and license agreement for a portfolio of preclinical rare disease gene therapy programs and enabling technologies from Pfizer. The acquisition cost AstraZeneca up to $1 billion, with the […]

Mergers and Acquisitions

AstraZeneca moves deeper into rare diseases, spending $150M on late-phase hematology prospect

September 29, 2021

Via: FierceBiotech

AstraZeneca is continuing to build out its rare disease pipeline, pulling the trigger on an option to buy Caelum Biosciences that it picked up in its takeover of Alexion. The buyout gives AstraZeneca control of a phase 3 treatment for […]

Mergers and Acquisitions

Another hurdle down as EU clears AstraZeneca’s Alexion takeover

July 7, 2021

Via: Pharmaphorum

The EU approval comes after the merger has already been okayed by the US, Japan and a number of other countries around the world, and AZ says it is now hoping to completing the transaction by the end of this […]